Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Cordoba – page 17

572 clinical trials in Cordoba, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Cordoba at a glance
572
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

572 trials in Cordoba

Open in trial search

Chronic kidney disease

Not yet recruiting

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Sjogren's syndrome

Not yet recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Vor Biopharma Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Dermatitis atopic

Not yet recruiting

Study of IMG-007 injection to treat moderate to severe atopic dermatitis in adults

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IMG-007
  • Sponsor:Inmagene LLC

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

A Randomized Study of Felzartamab versus Placebo to Assess Efficacy and Safety in Adults with Graves’ Disease

Not yet recruiting
Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

Bladder transitional cell carcinoma

Not yet recruiting

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Cordoba

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on novel treatments for various cancer types, including metastatic colorectal cancer, non-small cell lung cancer, and prostate cancer. Studies evaluate innovative therapeutic approaches and combination treatments.

  • Colorectal Cancer Therapeutics
  • Prostate Cancer Treatments
  • Lung Cancer Interventions

Investigations include targeted therapies and immunotherapy combinations for improved patient outcomes.

02 Immunology Studies

Comprehensive research into autoimmune conditions, including systemic sclerosis, atopic dermatitis, and psoriatic arthritis. Clinical trials evaluate new biological treatments and their effectiveness.

  • Autoimmune Disease Therapies
  • Dermatological Conditions
  • Inflammatory Disorders

Focus on developing targeted treatments for chronic inflammatory conditions.

03 Infectious Disease Prevention

Vaccine development studies targeting cytomegalovirus (CMV) and respiratory syncytial virus (RSV). Research aims to prevent infections in vulnerable populations.

  • Viral Infection Prevention
  • Vaccine Development
  • Immune Response Studies

Emphasis on vaccine efficacy and safety in different age groups.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.